GDRXGoodRx Holdings, Inc.

Nasdaq goodrx.com


$ 8.62 $ -0.13 (-1.49 %)    

Wednesday, 07-Aug-2024 15:59:55 EDT
QQQ $ 431.72 $ -4.76 (-1.08 %)
DIA $ 387.79 $ -2.19 (-0.56 %)
SPY $ 518.50 $ -3.49 (-0.67 %)
TLT $ 95.87 $ -0.68 (-0.7 %)
GLD $ 220.55 $ -0.15 (-0.07 %)
$ 8.61
$ 8.61 x 100
$ 8.63 x 794
-- - --
$ 4.14 - $ 9.26
2,147,882
na
3.36B
$ 1.95
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-12-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 boehringer-ingelheim-and-goodrx-team-up-to-offer-low-cost-humira-biosimilar

 Boehringer Ingelheim and GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., announced today a patien...

 goodrx-debuts-prescription-cost-tracker-aims-to-address-prescription-affordability-and-price-transparency-issues-highlights-high-medication-costs-reduced-insurance-coverage-and-increased-friction-as-key-factors

Reveals Consumers Paid $21B Out-of-Pocket in 2024, Averaging $16.26 Per Prescription

 morgan-stanley-maintains-equal-weight-on-goodrx-holdings-raises-price-target-to-95

Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and raises the price tar...

 goodrx-strengthens-core-business-with-new-initiatives-analyst-upgrades-on-potential-opportunities

GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contrac...

 rbc-capital-upgrades-goodrx-holdings-to-outperform-raises-price-target-to-10

RBC Capital analyst Mark Mahaney upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Perform to Outperform and raises the pri...

 barclays-maintains-overweight-on-goodrx-holdings-raises-price-target-to-10

Barclays analyst Stephanie Davis maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from ...

 raymond-james-upgrades-goodrx-holdings-to-outperform-announces-10-price-target

Raymond James analyst John Ransom upgrades GoodRx Holdings (NASDAQ:GDRX) from Market Perform to Outperform and announces $10...

 td-cowen-maintains-buy-on-goodrx-holdings-raises-price-target-to-16

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $14 to $16.

 goodrx-shares-soar-nearly-10-as-new-partnership-with-kroger-promises-big-savings

GoodRX shares surged nearly 10% Wednesday afternoon following the announcement of a new direct contracting agreement with Kroge...

 change-healthcare-cyberattack-goodrx-expects-low-single-digit-million-dollar-impact-in-2024

GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and ph...

 goodrx-holdings-analyst-turns-bullish-ahead-of-q1-earnings

GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst.

 keybanc-upgrades-goodrx-holdings-to-overweight-announces-9-price-target

Keybanc analyst Scott Schoenhaus upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Weight to Overweight and announces $9 pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION